Feb 11, 2026 · Breaking update
Loyal raises $100M Series C, bringing total funding to $250M+
Loyal announced a $100M Series C on Feb 11, 2026, led by age1 (Laura Deming's Longevity Fund) and Baillie Gifford. This brings total company funding to $250M+ and strengthens execution confidence across LOY-001, LOY-002, and LOY-003.
Why this matters for owners:
• More capital supports manufacturing, regulatory execution, and commercial readiness.
• LOY-002 timelines remain tied to remaining manufacturing review milestones.
• The broader Loyal pipeline (LOY-001/002/003) now has stronger financial backing.
Get LOY-002 updates before anyone else
Join 1,200+ dog owners tracking the first FDA dog longevity drug.
We'll only email you about LOY-002 approval milestones. Unsubscribe anytime.
Want a personalized longevity plan for your dog?
Get a custom health score, breed-specific insights, and LOY-002 eligibility in 2 minutes.
Both tools are 100% free. No signup required to start.